Free Trial
TSE:ONC

Oncolytics Biotech (ONC) Stock Price, News & Analysis

Oncolytics Biotech logo
C$14.90 -0.20 (-1.32%)
As of 09/3/2025

About Oncolytics Biotech Stock (TSE:ONC)

Advanced

Key Stats

Today's Range
C$14.90
C$14.90
50-Day Range
C$1.17
C$18.60
52-Week Range
C$0.44
C$2.08
Volume
280 shs
Average Volume
169,589 shs
Market Capitalization
C$1.50 billion
P/E Ratio
N/A
Dividend Yield
0.31%
Price Target
C$3.50
Consensus Rating
Buy

Company Overview

Oncolytics Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

ONC MarketRank™: 

Oncolytics Biotech scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oncolytics Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

  • Downside Risk

    Oncolytics Biotech has a consensus price target of C$3.50, representing about 76.5% downside from its current price of C$14.90.

  • Amount of Analyst Coverage

    Oncolytics Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Oncolytics Biotech's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oncolytics Biotech is -40.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oncolytics Biotech is -40.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oncolytics Biotech has a P/B Ratio of 126.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ONC.
  • Dividend Yield

    Oncolytics Biotech has a dividend yield of 0.31%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Oncolytics Biotech does not have a long track record of dividend growth.

  • Read more about Oncolytics Biotech's dividend.
  • Short Interest

    There is no current short interest data available for ONC.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Oncolytics Biotech this week, compared to 2 articles on an average week.
  • Search Interest

    14 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oncolytics Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$178,192.00 in company stock and sold C$0.00 in company stock.

  • Percentage Held by Insiders

    Only 3.82% of the stock of Oncolytics Biotech is held by insiders.

  • Percentage Held by Institutions

    Only 0.07% of the stock of Oncolytics Biotech is held by institutions.

  • Read more about Oncolytics Biotech's insider trading history.
Receive ONC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ONC Stock News Headlines

Crypto Gets Official Government Backing—Here's the Winner
Trump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really investing in this coin.tc pixel
Oncolytics Biotech Announces AGM Voting Results
See More Headlines

ONC Stock Analysis - Frequently Asked Questions

Oncolytics Biotech's stock was trading at C$1.33 at the beginning of 2025. Since then, ONC stock has increased by 1,020.3% and is now trading at C$14.90.

Oncolytics Biotech Inc. (TSE:ONC) posted its earnings results on Tuesday, November, 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.01.

Shares of ONC stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Ballard Power Systems (BLDP), (ONCYF) (ONCYF), Resverlogix (RVX), Birchcliff Energy (BIR), Enbridge (ENB) and

Company Calendar

Last Earnings
11/12/2024
Today
9/18/2025

Industry, Sector and Symbol

Stock Exchange
TSE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
TSE:ONC
CIK
N/A
Fax
N/A
Employees
29
Year Founded
N/A

Price Target and Rating

High Price Target
C$3.50
Low Price Target
C$3.50
Potential Upside/Downside
-76.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
C($0.37)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-C$27.66 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-141.94%
Return on Assets
-71.33%

Debt

Debt-to-Equity Ratio
11.75
Current Ratio
2.99
Quick Ratio
8.86

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$3.53 per share
Price / Cash Flow
4.22
Book Value
C$0.12 per share
Price / Book
126.70

Miscellaneous

Outstanding Shares
100,361,000
Free Float
N/A
Market Cap
C$1.50 billion
Optionable
Not Optionable
Beta
0.80
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (TSE:ONC) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners